Indian Essential Drugs List Heralds Price Caps On Hep C Products
This article was originally published in Scrip
Executive Summary
India has announced its national list of essential medicines (NLEM) 2015, which covers a total of 376 drugs across 30 therapeutic segments, including those such as sofosbuvir, pegylated interferon alfa 2a and 2b, raltegravir, trastuzumab, and rituximab, as against 348 medicines across 27 segments listed in NLEM 2011.
You may also be interested in...
Pharma Readies For Price Caps On Glargine, Teneligliptin, Lenalidomide In India
India’s national list of essential medicines 2022 features 34 additions, including insulin glargine, teneligliptin, lenalidomide, bedaquiline and montelukast, with price control expected to follow on these drugs.
Pharma Readies For Price Caps On Glargine, Teneligliptin, Lenalidomide In India
India’s national list of essential medicines 2022 features 34 additions, including insulin glargine, teneligliptin, lenalidomide, bedaquiline and montelukast, with price control expected to follow on these drugs.
Biocon Pumps Up For Adalimumab US Debut Amid Payer ‘Steady State’
Biocon is confident of its “four channel strategy” for the upcoming debut of biosimilar Humira in the US and also asserts it’s well positioned to compete when price cuts come into play for Sanofi’s Lantus next year.